Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: May 19, 2009

Premium

Jim Merryweather has become vice president of business development at NextBio. Most recently, he was vice president of strategic planning and business development at Applied Biosystems. Prior to that, he was executive vice president for sales and marketing and executive vice president of pharmaceutical corporate development at Ciphergen Biosystems. Before that, he held several positions at Incyte. Merryweather holds a PhD in biochemistry from Washington State University and a BS in chemistry from Northern Illinois University.


Robert Hariri has joined the board of directors of WaferGen Biosystems. He is the CEO of Celgene Cellular Therapeutics. He is also a member of the scientific advisory board for the Archon X Prize for Genomics.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.